'Blockbuster potential' for Australian firm's immuno-oncology pipeline

23 January 2017
2019_biotech_test_vial_discovery_big

Australian biotech company Prima BioMed (ASX: PRR) will present research into its lead immuno-oncology candidate, IMP321, at the 2nd Annual Cancer Immunotherapy Conference in San Francisco next month.

The drug is in Phase II development against metastatic breast cancer and also in Phase I development in melanoma in combination with Keytruda (pembrolizumab), according to a report from Van Leeuwenhoeck Research analyst Marcel Wijma.

Prima acquired the rights to IMP321 when it bought the privately held French immunotherapy company Immutep in 2014, becoming a front-runner in LAG-3 technology.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology